1.19
-0.07(-5.56%)
Currency In USD
Address
1800 El Camino Real
Menlo Park, CA 94027
United States of America
Phone
650-331-9090
Sector
Healthcare
Industry
Biotechnology
Employees
22
First IPO Date
March 25, 2022
| Name | Title | Pay | Year Born |
| Mr. Eric E. Easom | Co-Founder, Chief Executive Officer, President & Chairman of the Board | 860,297 | 1969 |
| Mr. Joseph S. Zakrzewski | Co-Founder & Independent Chairman of the Board | 64,577 | 1962 |
| Mr. Joshua M. Eizen J.D. | Chief Legal Officer, Chief Operating Officer & Corporate Secretary | 565,988 | 1978 |
| Ms. Lucy O. Day CPA | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 588,860 | 1960 |
| Mr. Vince Hernandez | Senior Vice President of Research & Head of Chemistry | 0 | N/A |
| Dr. George Harrison Talbot FACP, M.D. | Co-Founder & Senior Clinical Advisor | 0 | 1948 |
| Dr. Michael R. K. Alley Ph.D. | Co-Founder, Senior Vice President of Research Fellow & Head of Biology | 0 | N/A |
| Dr. Sanjay Chanda Ph.D. | Chief Development Officer | 0 | 1966 |
| Dr. Stephen David Prior Ph.D. | Chief Strategy Officer | 0 | 1958 |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.